Last reviewed · How we verify
RVL-1201
RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle.
RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle. Used for Presbyopia (age-related loss of accommodation), Reduced pupil size associated with presbyopia.
At a glance
| Generic name | RVL-1201 |
|---|---|
| Also known as | Oxymetazoline Hydrochloride Ophthalmic Solution 0.1% |
| Sponsor | RVL Pharmaceuticals, Inc. |
| Drug class | Alpha-1A adrenergic agonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
RVL-1201 works as a selective alpha-1A adrenergic receptor agonist, causing contraction of the dilator pupillae muscle in the iris to produce mydriasis. This mechanism is used to improve pupil function and visual performance in patients with presbyopia or reduced pupil size. The drug is administered as an ophthalmic solution applied directly to the eye.
Approved indications
- Presbyopia (age-related loss of accommodation)
- Reduced pupil size associated with presbyopia
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Mydriasis-related visual effects
- Headache
Key clinical trials
- Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis (PHASE1, PHASE2)
- Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (PHASE3)
- Study of Safety of RVL-1201 in Treatment of Blepharoptosis (PHASE3)
- Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RVL-1201 CI brief — competitive landscape report
- RVL-1201 updates RSS · CI watch RSS
- RVL Pharmaceuticals, Inc. portfolio CI